U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O.Zn
Molecular Weight 81.395
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC OXIDE

SMILES

[O-2].[ZnH2+2]

InChI

InChIKey=RNWHGQJWIACOKP-UHFFFAOYSA-N
InChI=1S/O.Zn/q-2;+2

HIDE SMILES / InChI

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Zn
Molecular Weight 65.3956
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

CNS Activity

Curator's Comment:: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Curator's Comment:: Centuries before zinc was recognized as a distinct element, zinc ores were used for making brass (a mixture of copper and zinc). A brass dating from between 1400-1000 BC has been found in Palestine. An alloy containing 87% zinc was found in prehistoric ruins in Transylvania. The smelting of zinc ores with copper was apparently discovered in Cyprus and was used later by the Romans. Metallic zinc was produced in the 13th century in India by reducing calamine (zinc carbonate, ZnCO3) with organic substances such as wool. The metal was rediscovered later in Europe. William Champion set up a zinc industry in Bristol (England) in the 1740s.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: ultraviolet B-induced damage
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
High-throughput computational and experimental techniques in structural genomics.
2004 Oct
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Erythrocyte zinc content in critically ill patients.
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
2005 Aug
Increased plasma levels of zinc in obese adult females on a weight-loss program based on a hypocaloric balanced diet.
2005 Nov-Dec
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Characterization and inhibition of SARS-coronavirus main protease.
2006
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Copper and zinc concentrations in serum of healthy Greek adults.
2006 Apr 15
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.
2009 Mar 28
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
2011 Mar 1
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Glucarpidase for the treatment of life-threatening methotrexate overdose.
2012 Nov
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Zinc oxide nanoparticles induce apoptosis by enhancement of autophagy via PI3K/Akt/mTOR inhibition.
2014 May 16
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
2015 Sep
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Effects of zinc fluoride on inhibiting dentin demineralization and collagen degradation in vitro: A comparison of various topical fluoride agents.
2016 Oct 1
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er3+ doped zinc fluoride glass.
2017 May 15
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:13:18 UTC 2021
Edited
by admin
on Fri Jun 25 21:13:18 UTC 2021
Record UNII
SOI2LOH54Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC OXIDE
EP   FCC   HSDB   II   INCI   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INCI  
Official Name English
ZINC OXIDE COMPONENT OF VUSION
Common Name English
ZINC OXIDE [WHO-DD]
Common Name English
C.I. 77947
Common Name English
ZINC OXIDE [USP-RS]
Common Name English
ZINC WHITE
Common Name English
ZINC (AS ZINC OXIDE) [VANDF]
Common Name English
ZINC OXIDE COMPONENT OF CALAMINE
Common Name English
CALAMINE COMPONENT ZINC OXIDE
Common Name English
CI 77947
INCI  
INCI  
Official Name English
C.I. PIGMENT WHITE 4
Common Name English
ZINCUM OXYDATUM
HPUS  
Common Name English
ZINC OXIDE NEUTRAL [USP MONOGRAPH]
Common Name English
ZINC OXIDE [MART.]
Common Name English
ZINC OXIDE EMULSION [VANDF]
Common Name English
ZINC OXIDE [WHO-IP]
Common Name English
ZINC PASTE [VANDF]
Common Name English
ZINC OXIDE [HSDB]
Common Name English
ZINC OXIDE [INCI]
Common Name English
ZINC OXIDE [ORANGE BOOK]
Common Name English
ZINC OXIDE [FCC]
Common Name English
ZINC OXIDE [EP MONOGRAPH]
Common Name English
ZINC OXIDE [II]
Common Name English
ZINCI OXYDUM [WHO-IP LATIN]
Common Name English
ZINC OXIDE [JAN]
Common Name English
ZINC OXIDE [VANDF]
Common Name English
CI 77947 [INCI]
Common Name English
ZINC (AS OXIDE) [VANDF]
Common Name English
VUSION COMPONENT ZINC OXIDE
Common Name English
ZINC OXIDE [USP]
Common Name English
ZINC PASTE
VANDF  
Common Name English
ZINC OXIDE [MI]
Common Name English
ZINCUM OXYDATUM [HPUS]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 178.3297
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 175.300
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 175.380
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 177.1460
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 177.1900
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
FDA ORPHAN DRUG 142401
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 310.531
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 352.20
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 352.10
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
WHO-VATC QA07XA91
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
Food Contact Sustance Notif, (FCN No.) FCN NO. 193
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
EPA PESTICIDE CODE 88502
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 347.10
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
NCI_THESAURUS C851
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 346.18
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 177.1350
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
CFR 21 CFR 176.170
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
Code System Code Type Description
DRUG BANK
DB09321
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
MERCK INDEX
M11617
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY Merck Index
PUBCHEM
3007857
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
WIKIPEDIA
ZINC OXIDE
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ZINC OXIDE
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY Description: A white or faintly yellowish white, very fine, amorphous powder, free from grittiness; odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in hydrochloric acid (~70 g/l) TS. Category: Mild astringent used topically as a protective. Storage: Zinc oxide should be kept in a well-closed container. Additional information: Zinc oxide gradually absorbs carbon dioxide from the air. Definition: Zinc oxide contains not less than 99.0% and not more than 100.5% of ZnO, calculated with reference to the freshly ignited substance.
EVMPD
SUB12623MIG
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
EPA CompTox
1314-13-2
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
MESH
D015034
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
DRUG CENTRAL
4240
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
USP_CATALOG
1724747
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY USP-RS
NCI_THESAURUS
C949
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
HSDB
5024
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
RXCUI
11423
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY RxNorm
CAS
1314-13-2
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201128
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
FDA UNII
SOI2LOH54Z
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
ECHA (EC/EINECS)
215-222-5
Created by admin on Fri Jun 25 21:13:19 UTC 2021 , Edited by admin on Fri Jun 25 21:13:19 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY